Should I take dabigatran etexilate capsules (Pradaxa) for a long time if I have atrial fibrillation?

Atrial fibrillation (atrial fibrillation arrhythmia) is an irregular heart rhythm disease that can easily cause blood to accumulate in the atrium, form blood clots, and increase the risk of stroke. Therefore, for patients with atrial fibrillation, anticoagulation therapy is a very important part of preventing stroke and other thrombosis-related events.

Dabigatran etexilate capsule (Pradaxa) is an oral direct thrombin inhibitor that is widely used for anticoagulation treatment in patients with non-valvular atrial fibrillation. For patients with atrial fibrillation, anticoagulation therapy usually needs to be continued long-term, not just during episodes of atrial fibrillation.

Although long-term use of dabigatran etexilate capsules can help prevent thrombotic events, the specific medication regimen needs to be based on the patient's overall health, other potential risk factors, and the professional advice of the doctor. Before using dabigatran etexilate capsules, patients should carefully consult their doctor to ensure the rationality and safety of the medication. In addition, regular medical monitoring and follow-up are important steps to ensure the patient's health during long-term medication use.

Dabigatran etexilate capsules have been launched in China and have been included in medical insurance. Patients can purchase them domestically. Please consult the local hospital pharmacy for specific prices. The main foreign drug is the original drug of dabigatran etexilate capsules. The cheaper one is the Turkish version of the original drug from Germany. The price of 110mg*60 capsules is about three to four hundred, and the ingredients and efficacy are consistent with the original drug on the domestic market.